A 14-year-old spayed female Maine Coon presents with chro...

Thank you for reaching out regarding this complex feline patient. A 14-year-old spayed female Maine Coon presenting with chronic polyuria/polydipsia (PU/PD) and weight loss, coupled with azotemia and hypokalemia, immediately raises several flags that warrant a thorough investigation beyond just the gabapentin dosing.

First, let's address the IRIS staging. With a creatinine of 3.5 mg/dL and an SDMA of 28 µg/dL, this cat is more accurately categorized as IRIS Stage 3 Chronic Kidney Disease, not Stage 2.
* IRIS Stage 2: Creatinine 1.6-2.8 mg/dL, SDMA 18-25 µg/dL
* IRIS Stage 3: Creatinine 2.9-5.0 mg/dL, SDMA 26-38 µg/dL
This distinction is critical as it significantly impacts drug elimination and overall prognosis.

Gabapentin Dosing in IRIS Stage 3 CKD

Gabapentin is primarily eliminated via renal excretion, with approximately 80% excreted unchanged in the urine. Therefore, in a patient with significant renal impairment like this cat, its half-life will be prolonged, leading to drug accumulation and an increased risk of adverse effects if not adjusted.

Standard Feline Dose: The typical starting dose for gabapentin in cats is 5-10 mg/kg orally every 8-12 hours, or often a flat dose of 50-100 mg/cat for situational anxiety or pain.

Dosage Adjustment for IRIS Stage 3 CKD:
Given the cat's IRIS Stage 3 CKD, a significant reduction in dose or extension of the dosing interval is necessary. My recommendation would be to reduce the dose by approximately 50% and/or extend the dosing interval.

* Option 1 (Dose Reduction): Start with 2.5-5 mg/kg orally every 12-24 hours. For a cat that might typically receive 50-100 mg, this would mean starting with 25-50 mg per dose.
* Option 2 (Interval Extension): Administer the standard dose (e.g., 50 mg/cat) every 24-48 hours, depending on clinical response and tolerance.

My preferred approach for a chronic condition: I would typically start with 2.5-5 mg/kg orally every 24 hours and monitor closely for efficacy and side effects. If the patient tolerates it well and requires more consistent pain/anxiety control, I might cautiously increase the frequency to every 12 hours, ensuring the total daily dose remains conservative.

Monitoring:
* Clinical Signs: Closely monitor for sedation, ataxia, and lethargy. These are common dose-limiting side effects, especially in renally impaired patients.
* Efficacy: Assess if the desired effect (pain control, anxiety reduction) is achieved at the lower dose.
* Renal Values: Continue to monitor renal parameters, as any further decline in kidney function would necessitate further dose adjustments.

Broader Clinical Considerations

While gabapentin dosing is important, I would be very concerned about the underlying clinical picture:

Hypokalemia: This is a common and serious complication in feline CKD. Hypokalemia can exacerbate renal dysfunction (nephrogenic diabetes insipidus), contribute to muscle weakness, and worsen lethargy. It needs to be addressed promptly.

* Recommendation: Supplementation with oral potassium gluconate (e.g., K-citrate, Tumil-K) at 2-5 mEq/cat/day, adjusted based on recheck potassium levels.

PU/PD and Weight Loss in a 14-year-old Maine Coon: This combination, even with CKD, demands a total T4 measurement. Hyperthyroidism is extremely common in older cats and can significantly impact renal function. It can mask the true severity of CKD by maintaining a higher GFR. Treating hyperthyroidism can sometimes lead to a worsening of azotemia, which needs careful management.

Further CKD Management: This cat is in IRIS Stage 3. Beyond addressing the hypokalemia and ruling out hyperthyroidism, a comprehensive CKD management plan is essential:

* Renal Diet: Transition to a phosphorus-restricted, protein-controlled renal diet. This is one of the most impactful interventions for CKD progression.
* Hydration: Ensure adequate hydration. This may involve increasing water intake (wet food, water fountains) or even subcutaneous fluid therapy if dehydrated or maintaining hydration is challenging.
* Phosphate Binders: Consider oral phosphate binders if serum phosphorus is elevated or trending high, even within the reference range, as this can accelerate CKD progression.
* Blood Pressure: Measure blood pressure. Hypertension is common in CKD and can worsen renal damage. If present, amlodipine would be indicated.

In summary, for this 14-year-old Maine Coon with IRIS Stage 3 CKD, I would initiate gabapentin at 2.5-5 mg/kg orally every 24 hours and monitor closely. However, my primary focus would be on addressing the hypokalemia, performing a total T4, and implementing a comprehensive CKD management plan.

Confidence Level: High confidence for gabapentin dosing principles in CKD; Moderate — need more data for full therapeutic plan without a T4 and full electrolyte panel.